CLINICAL USE

Induction and maintenance of remission in ulcerative colitis

DOSE IN NORMAL RENAL FUNCTION

Dose depends on preparation

PHARMACOKINETICS

  • Molecular weight                           :153.1
  • %Protein binding                           :40–50
  • %Excreted unchanged in urine     : No data
  • Volume of distribution (L/kg)       :No data
  • half-life – normal/ESRD (hrs)      :0.6/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Caution – use only if necessary. Start with low dose and increase according to response
  • 10 to 20     : Caution – use only if necessary. Start with low dose and monitor closely
  • <10           : Caution – use only if necessary. Start with low dose and monitor closely

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in GFR <10 mL/min
  • HD                     :Unlikely to be dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral, PR

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Mesalazine is excreted rapidly by the kidney, mainly as its metabolite N-acetyl-5-aminosalicylic acidNephrotoxicity has been reported Mesalazine is best avoided in patients with established renal impairment, but if necessary should be used with caution, and the patient carefully monitored

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia